Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal irinotecan + 5-FU/LV vs sequential nab-paclitaxel + S-1 as second-line therapy in advanced biliary tract cancer
ChiCTR2500111686Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Nov 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nanoliposomal irinotecan, nab-paclitaxel, tegafur + gimeracil + oteracil, fluorouracil and folinic acid in biliary cancer, intrahepatic cholangiocarcinoma (ICC), cholangiocarcinoma (CCA) and 1 more (2 arms), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecannab-paclitaxeltegafur + gimeracil + oteracilfluorouracilfolinic acid
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2500111686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111686.